第四代表皮生长因子受体-酪氨酸激酶抑制剂：希望与挑战 - Suppr

Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges.

作者信息

Su Chunxia, Sun Shi-Yong

机构信息

Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.

出版信息

Transl Cancer Res. 2024 Aug 31;13(8):3929-3934. doi: 10.21037/tcr-24-406. Epub 2024 Jul 25.

DOI:10.21037/tcr-24-406

PMID:39262457

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11384918/

Abstract

摘要

相似文献

Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges.

Transl Cancer Res. 2024 Aug 31;13(8):3929-3934. doi: 10.21037/tcr-24-406. Epub 2024 Jul 25.

Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?

Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350.

Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.

Cancer Med. 2023 Jan;12(1):159-169. doi: 10.1002/cam4.4918. Epub 2022 Jun 15.

Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.

Clin Oncol (R Coll Radiol). 2022 Nov;34(11):e451-e462. doi: 10.1016/j.clon.2022.06.003. Epub 2022 Jul 7.

Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer.

Expert Opin Drug Saf. 2024 Aug;23(8):1007-1015. doi: 10.1080/14740338.2023.2294924. Epub 2023 Dec 18.

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.

Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8.

Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.

Indian J Cancer. 2017 Dec;54(Supplement):S37-S44. doi: 10.4103/ijc.IJC_532_17.

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.

Bioorg Chem. 2022 Nov;128:106057. doi: 10.1016/j.bioorg.2022.106057. Epub 2022 Aug 1.

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.

Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).

Ann Transl Med. 2018 Apr;6(8):140. doi: 10.21037/atm.2017.10.04.

引用本文的文献

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer.

Curr Issues Mol Biol. 2025 Jun 30;47(7):498. doi: 10.3390/cimb47070498.

本文引用的文献

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.

Clin Cancer Res. 2023 Aug 15;29(16):3004-3016. doi: 10.1158/1078-0432.CCR-22-3901.

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.

J Med Chem. 2022 Jul 28;65(14):9662-9677. doi: 10.1021/acs.jmedchem.2c00704. Epub 2022 Jul 15.

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.

Nat Cancer. 2022 Apr;3(4):402-417. doi: 10.1038/s43018-022-00351-8. Epub 2022 Apr 14.

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.

Cancer Sci. 2022 Feb;113(2):709-720. doi: 10.1111/cas.15229. Epub 2021 Dec 16.

Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.

N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.

Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors.

J Med Chem. 2019 Nov 27;62(22):10272-10293. doi: 10.1021/acs.jmedchem.9b01169. Epub 2019 Nov 13.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.

Cancer Discov. 2019 Jul;9(7):926-943. doi: 10.1158/2159-8290.CD-18-0903. Epub 2019 May 15.

Discovery of JND3229 as a New EGFR Mutant Inhibitor with In Vivo Monodrug Efficacy.

ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127. doi: 10.1021/acsmedchemlett.8b00373. eCollection 2018 Nov 8.

Targeting EGFR and EGFR resistance mutations in NSCLC: Current developments in medicinal chemistry.

Med Res Rev. 2018 Sep;38(5):1550-1581. doi: 10.1002/med.21488. Epub 2018 Jan 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献